About us

Jérôme Marzinski is a seasoned medtech leader, having held a variety of senior roles over a more than 25 year career, with significant experience in scaling venture capital and private equity-funded businesses in the sector, having completed 15 M&A transactions and raised over €50m of growth capital. Most recently Jérôme was the Interim Chief Executive Officer of Cimon Medical, overseeing the CE mark clearance for the Company’s lead product under new Medical Device Regulations. Prior to this, he spent three years as Chief Executive Officer at Visiometrics, spent six years in senior positions at ev3, and was Chief Operating Officer at Vexim. Jérôme has an MA in corporate financing and accounting from the University of Lille, and in 2012 completed the TRIUM Global Executive MBA, jointly issued by New York University Stern School of Business, London School of Economics and Political Science, and HEC Paris School of Management.

Dr Matthew Frohn graduated from Oxford Brookes University with a BSc Degree in Cell and Molecular Biology followed by a D.Phil in Biochemistry from Oxford University. He worked on research collaborations with Zeneca, and a short research post with a British Biotech subsidiary before joining Oxford Technology Management in 1999. He is currently a partner of Longwall Venture Partners where he is particularly involved with its life science investments. He became a Non-Executive Director of OxSonics™ in November 2013.

Professor Constantin holds BA, MEng, MA and PhD degrees in Engineering from the University of Cambridge, and was elected to the first statutory chair in Biomedical Engineering at the University of Oxford in 2011, where he serves as the Director of the Institute of Biomedical Engineering. He is the author of over 100 peer-reviewed publications and 16 patents in the fields of drug delivery, acoustic cavitation and therapeutic ultrasound. Prof. Coussios received the UK’s Institute of Acoustics’ Young Person’s Award for Innovation in Acoustical Engineering in 2007, was elected as Secretary-General of the International Society for Therapeutic Ultrasound between 2006-2010 and was honoured with the Society’s Fred Lizzi award in 2012. He was elected as the youngest ever Fellow of the Acoustical Society of America in 2009 for contributions to biomedical ultrasound, and received the Society’s Bruce Lindsay award in 2012. In 2022 Prof. Coussios was awarded of Officer of the Order of the British Empire (OBE) in the Queen’s birthday honours list, for Services to Biomedical Engineering.

George Robinson is a partner of Sloane Robinson LLP, an investment management business specialising in global equities which he co-founded in 1993. Prior to that, he worked in Asia for 15 years, initially for John Swire & Sons in Hong Kong, Korea and the Philippines, and then for Asia-based stockbroker WI Carr in Korea, Thailand and Hong Kong where he was Director of Regional Research. Mr Robinson graduated with a BA in Engineering Science from Keble College, Oxford in 1979, and is an honorary fellow of Keble College, Oxford as well as a former member of the Oxford University Endowment Investment Committee.

David has over 25 years’ experience in financial, commercial and operational roles. After graduating with a BSc in Management from the University of Aston he joined Price Waterhouse (now PricewaterhouseCoopers) qualifying as a Chartered Accountant in 1993. He has broad, multi-sector experience in high-growth, entrepreneurial businesses from start-ups to listed companies. After an early career with Bryant Group plc and Homeserve plc, David has spent the last 10 years supporting early-stage technology businesses, most recently at Celixir plc (biotech) and Creavo Medical Technologies Ltd (medical devices). He has significant transaction experience including multiple fundraisings and acquisitions, and key outsourcing and out-licencing contracts. David joined OxSonics Ltd as Finance Director in September 2021.

Dr Cliff Rowe holds a BSc (hons) in Pharmacology from the University of Liverpool and a PhD in Molecular Toxicology from the University of Aberdeen. Cliff has worked on academic pharmacology and drug safety projects at the Universities of Aberdeen, Manchester and at the MRC Centre for Drug Safety Sciences (University of Liverpool). Cliff was previously Principal Scientist at CN BioInnovations where he managed internal research activities and worked on international multi-centre collaborative projects with partners across Europe and the USA. Cliff joined OxSonics as Principal Scientist in April 2015 to work on in-house development programs and co-development projects with strategic partners.

Dr Calum Crake has over 12 years’ experience in medical device research and development, spanning academic research, commercial product development and deployment to the clinic. He has a background in biomedical engineering, with extensive experience in medical imaging, therapeutic ultrasound and drug delivery. Calum joined OxSonics from Harvard Medical School and Brigham & Women’s Hospital, where he led the development of novel ultrasound transducers and passive acoustic imaging techniques for monitoring MR-guided focused ultrasound delivery to the brain, as well as use of nanoemulsion cavitation agents for ablation of solid tumours. In his earlier career Calum worked for Evercore Partners in the investment banking industry, where his work included advising Pace on their $475m acquisition of 2Wire and QIA on their €400m investment in Hochtief. Calum has MEng and PhD degrees in engineering from the University of Oxford.

Andy Rogers has over 25 years experience within the Quality and Regulatory environment in both the Medical Device and Pharmaceutical industries, working across a range of businesses including Abbott Laboratories, Novartis, Martindale and Vygon. Andy joined OxSonics from DnaNudge, where he was responsible for developing and implementing the global regulatory strategy. He holds a BSc (Hons) degree in Pharmaceutical Sciences, a PG cert in Medical Device Quality Assurance and Regulatory Affairs and is a Member of the Royal Society of Chemistry (MRSC).

Professor Fergus Gleeson is a Consultant Radiologist and Professor of Radiology in Oxford. He trained in Cambridge, Papworth and London, and was a Fellow in Radiology at UCLA in Los Angeles. He was appointed to Oxford in 1992, and is head of academic radiology, the director of the Oxford Imaging Trials Unit, and a Divisional Director for the Oxford University Hospitals NHS Trust. He advises OxSonics on the clinical administration of ultrasound with regards to patient care, use and usability, and technical performance.

Hardev Pandha is a clinician scientist and medical oncologist who graduated in medicine at the University of Birmingham. He trained in internal medicine and subsequently in medical oncology at the Royal Postgraduate Medical School at Hammersmith Hospital, London. He completed his PhD (Imperial College) in the Imperial Cancer Research Fund labs at the Hammersmith. He was a visiting fellow at Stanford University prior to completing his medical oncology training at the Royal Marsden Hospital, London. He was a senior lecturer in tumour immunology and medical oncology at St Georges, University of London in 2000 before being appointed Prof of Urological Oncology at the University of Surrey in 2006. His areas of expertise include the management of patients with Urological cancers and malignant melanoma. He has a key interest in early phase clinical trials involving targeted agents and the translational aspects of novel therapies. His portfolio includes gene and viral therapy as well as immunotherapy and small molecule inhibitors. His laboratory interests reflect this and in particular a combination of novel and biological therapies with more conventional treatments. His lab team have evolved a robust infrastructure of patient sample procurement and biobanking for translational research.

Robert is a Consultant Hepatobiliary Surgeon and NIHR Researcher from Aintree University Hospital and the University of Liverpool. His main research interests are focused on optimising multidisciplinary decision making around advanced colorectal cancer, non-surgical liver-directed therapies as well as better methods of identifying patients who may benefit from surgical resection for metastatic disease – so called “precision surgery”.